<VariationArchive RecordType="classified" VariationID="14476" VariationName="NC_000005.9:g.(?_126102443)_(126199753_?)dup" VariationType="Duplication" Accession="VCV000014476" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-05-07" DateCreated="2016-03-20" MostRecentSubmission="2016-03-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="29515" VariationID="14476">
      <GeneList>
        <Gene Symbol="LMNB1" FullName="lamin B1" GeneID="4001" HGNC_ID="HGNC:6637" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>5q23.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="5" Accession="NC_000005.10" start="126776623" stop="126837020" display_start="126776623" display_stop="126837020" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" start="126112314" stop="126172711" display_start="126112314" display_stop="126172711" Strand="+" />
          </Location>
          <OMIM>150340</OMIM>
          <Haploinsufficiency last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LMNB1">No evidence available</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LMNB1">Sufficient evidence for dosage pathogenicity</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000005.9:g.(?_126102443)_(126199753_?)dup</Name>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>5q23.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="5" Accession="NC_000005.9" innerStart="126102443" innerStop="126199753" display_start="126102443" display_stop="126199753" variantLength="97311" />
      </Location>
      <OtherNameList>
        <Name>DUP, CHR5:126,102,443-126,199,753 SRO, GRCh37</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000005.9" sequenceAccession="NC_000005" sequenceVersion="9" change="g.(?_126102443)_(126199753_?)dup" Assembly="GRCh37">
            <Expression>NC_000005.9:g.(?_126102443)_(126199753_?)dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="150340.0001" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 150340.0001 from the location reported by OMIM.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000005.9:g.(?_126102443)_(126199753_?)dup AND Adult-onset autosomal dominant demyelinating leukodystrophy" Accession="RCV000015563" Version="24">
        <ClassifiedConditionList TraitSetID="6383">
          <ClassifiedCondition DB="MedGen" ID="C1868512">Adult-onset autosomal dominant demyelinating leukodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2013-08-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2013-08-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2016-03-20" MostRecentSubmission="2016-03-20">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16951681</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21909802</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19151023</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21225301</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23649844</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6383" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5402" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Leukodystrophy, adult-onset, autosomal dominant</ElementValue>
                <XRef ID="Pelizaeus-Merzbacher+disease%2C+late-onset+type/5644" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pelizaeus-Merzbacher disease, autosomal dominant or late-onset type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Multiple sclerosis-like disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pelizaeus-Merzbacher disease, late-onset type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Autosomal Dominant Leukodystrophy with Autonomic Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Adult-onset autosomal dominant demyelinating leukodystrophy</ElementValue>
                <XRef ID="MONDO:0008215" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ADLD</ElementValue>
                <XRef Type="MIM" ID="169500" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">LMNB1-related autosomal dominant leukodystrophy (ADLD) is a slowly progressive disorder of central nervous system white matter characterized by onset of autonomic dysfunction in the fourth to fifth decade, followed by pyramidal and cerebellar abnormalities resulting in spasticity, ataxia, and tremor. Autonomic dysfunction can include bladder dysfunction, constipation, postural hypotension, erectile dysfunction, and (less often) impaired sweating. Pyramidal signs are often more prominent in the lower extremities (e.g., spastic weakness, hypertonia, clonus, brisk deep tendon reflexes, and bilateral Babinski signs). Cerebellar signs typically appear at the same time as the pyramidal signs and include gait ataxia, dysdiadochokinesia, intention tremor, dysmetria, and nystagmus. Many individuals have sensory deficits starting in the lower limbs. Pseudobulbar palsy with dysarthria, dysphagia, and forced crying and laughing may appear in the seventh or eighth decade. Although cognitive function is usually preserved or only mildly impaired early in the disease course, dementia and psychiatric manifestations can occur as late manifestations. Affected individuals may survive for decades after onset.</Attribute>
                <XRef ID="NBK338165" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">LMNB1-Related Autosomal Dominant Leukodystrophy</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10587" />
                <XRef ID="10587" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="Decipher">
                <URL>https://decipher.sanger.ac.uk/syndrome/59</URL>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">26749591</ID>
                <ID Source="BookShelf">NBK338165</ID>
              </Citation>
              <XRef ID="99027" DB="Orphanet" />
              <XRef ID="C1868512" DB="MedGen" />
              <XRef ID="MONDO:0008215" DB="MONDO" />
              <XRef Type="MIM" ID="169500" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="35828" SubmissionDate="2016-03-18" DateLastUpdated="2016-03-20" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="150340.0001_LEUKODYSTROPHY, ADULT-ONSET, AUTOSOMAL DOMINANT" title="LMNB1, DUP, CHR5:126,102,443-126,199,753 SRO, GRCh37_LEUKODYSTROPHY, ADULT-ONSET, AUTOSOMAL DOMINANT" />
        <ClinVarAccession Accession="SCV000035828" DateUpdated="2016-03-20" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2013-08-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 2 families of Irish American descent and in 2 other families with autosomal dominant adult-onset leukodystrophy (169500), Padiath et al. (2006) found a duplication of the LMNB1 gene and part of the MARCH3 gene (613333). Haplotype analysis suggested that the 2 Irish American families arose through a common founder.</Attribute>
              <Citation>
                <ID Source="PubMed">16951681</ID>
              </Citation>
              <XRef DB="OMIM" ID="169500" Type="MIM" />
              <XRef DB="OMIM" ID="613333" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In affected members of 4 unrelated families with ADLD, Schuster et al. (2011) found duplication of the LMNB1 gene and part of the MARCH3 gene. All 4 duplications were of different sizes, ranging from 107 to 218 kb, supporting independent events. Five patients from 2 families had about a 2-fold increased level of LMNB1 protein in white blood cells, and LMNB1 mRNA was also increased compared to controls. MARCH3 mRNA was not increased in patient leukocytes. Schuster et al. (2011) concluded that an accurate molecular diagnosis of the disorder could be made by direct analysis of LMNB1 in peripheral leukocytes.</Attribute>
              <Citation>
                <ID Source="PubMed">21225301</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">In a symptomatic man with ADLD and his asymptomatic sister who had leukodystrophy on brain imaging, Dos Santos et al. (2012) identified a 148-kb duplication on chromosome 5q23.2 including the LMNB1 gene, but not the MARCH3 gene. The findings confirmed the central role of the LMNB1 gene in ADLD.</Attribute>
              <Citation>
                <ID Source="PubMed">21909802</ID>
              </Citation>
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Using a custom array, Giorgio et al. (2013) performed detailed breakpoint junction sequence analysis of the duplicated 5q23 region containing the LMNB1 gene in 20 independent families with ADLD in whom genomic LMNB1 duplication was initially identified by aCGH, QT-PCR, or MLPA. Seven families had previously been reported (Brussino et al., 2009; Schuster et al., 2011; Dos Santos et al., 2012). There were a total of 16 unique rearrangements. Three of the duplications were shared by more than 1 family: 1 was found in 3 families and the other 2 duplications were found in 2 families each. Individuals with identical junctions shared the same haplotype, consistent with a founder effect. Duplication sizes ranged from about 128 kb to 475 kb. The largest duplication also included the PHAX (604924), ALDH7A1 (107323), and GRAMD3 genes. Comparison of all the samples identified a 72-kb minimal critical duplicated region required for ADLD that contained only the LMNB1 gene. All but 1 of the duplications were in the direct tandem orientation; the remaining duplication was inverted. Characterization of the junction sequences showed that most (11 of 15) showed short stretches of microhomology overlap ranging from 1 to 6 nucleotides, whereas the others showed small insertions at the breakpoints. All duplications resulted from intrachromosomal rearrangements. Analysis of the genomic architecture suggested several potential mechanisms for the duplications, including nonhomologous end joining (NHEJ) or fork stalling and template switching/microhomology-mediated break-induced repair (FoSTeS/MMBIR). The enrichment of Alu repetitive elements at the centromeric breakpoints (found in 4 cases), higher GC content, and high frequency of repetitive sequences at breakpoints likely also played a role in mediating ADLD duplications. RT-PCR of patients fibroblasts or blood showed increased LMNB1 expression (2.1- to 4.8-fold compared to controls), as well as increased protein levels (1.6- to 3.2-fold compared to controls). There was no apparent difference in phenotype according to duplication size, with the exception of the 1 family with a large inverted duplication affecting multiple genes.</Attribute>
              <Citation>
                <ID Source="PubMed">23649844</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">19151023</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">21225301</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">21909802</ID>
              </Citation>
              <XRef DB="OMIM" ID="604924" Type="MIM" />
              <XRef DB="OMIM" ID="107323" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LMNB1" />
          </GeneList>
          <Name>LMNB1, DUP, CHR5:126,102,443-126,199,753 SRO, GRCh37</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">DUP, CHR5:126,102,443-126,199,753 SRO, GRCh37</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="150340.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LEUKODYSTROPHY, ADULT-ONSET, AUTOSOMAL DOMINANT</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="35828" TraitType="Disease" MappingType="Name" MappingValue="LEUKODYSTROPHY, ADULT-ONSET, AUTOSOMAL DOMINANT" MappingRef="Preferred">
        <MedGen CUI="C1868512" Name="Adult-onset autosomal dominant demyelinating leukodystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

